111 Capital’s Agilon Health AGL Stock Holding History

111 Capital’s Portfolio AGL Stock Details AGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-625	Closed	-$35.9K	–	446
2025 Q2	$35.9K	Buy	+625	New	+$50.1K	0.01%	495

Other funds holding AGL

CDR

Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NPCM

North Peak Capital Management New York $601M AUM 0.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

111 Capital's AGL Position: Q3 2025 in Review

111 Capital sold out of Agilon Health (AGL) in Q3 2025, closing a stake of 625 shares — an estimated $35.9K sold.

111 Capital first reported a position in AGL in Q2 2025 and held it in 1 quarter. The position peaked at $35.9K in Q2 2025. 190 funds tracked by Wall St. Rank hold AGL as of Q3 2025.

111 Capital reported no remaining Agilon Health position as of Q3 2025 after selling out during the quarter.
111 Capital sold 625 Agilon Health shares in Q3 2025, an estimated $35.9K.
111 Capital first reported a position in Agilon Health in Q2 2025 and held it in 1 quarter.
111 Capital's Agilon Health position peaked at $35.9K in Q2 2025.
190 funds tracked by Wall St. Rank held Agilon Health as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.